India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
This article was originally published in The Pink Sheet Daily
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
You may also be interested in...
Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.
Action marks a change in firm’s commercialization policy toward the Southeast Asian nation.
Shanghai-based center will focus on Alzheimer’s, multiple sclerosis and Parkinson’s.